Compare Cassava Sciences Inc (FLNA) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Manchester United PLC — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Manchester United PLC trades at $22.22 (market cap $3.86B). The key difference: Manchester United PLC is far larger — about 72.6× Cassava Sciences Inc's market cap, and Manchester United PLC pays a 1.26% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MANU | |
|---|---|---|
Market Cap | $53.14M | $3.86B |
Sector | Health | Media |
52-Week High | $4.64 | $23.53 |
52-Week Low | $1.09 | $15.10 |
Enterprise Value | -$33.43M | $4.78B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Manchester United (MANU) trades at $22.24, up 0.86% with neutral technical signals. The company shows improving fundamentals with revenue growth to $667M in 2025 and recent Champions League qualification driving future revenue potential. However, profitability remains challenged with negative net margins and ROE. The stock faces mixed analyst sentiment with 40% buy ratings amid ongoing stadium development plans and ownership uncertainty.
Investment outlook balances stadium expansion upside against persistent profitability challenges. The $1.6B stadium project represents long-term value creation, but current negative earnings and high debt levels require careful monitoring. Near-term catalysts include Champions League revenue and potential ownership changes, while execution risks and competitive pressures remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
